Syon Capital’s BridgeBio Pharma BBIO Stock Holding History

Syon Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$951K	Sell	12,771 -340	-3%	-$23.8K	0.04%	372
2026 Q1	$974K	Sell	13,111 -60	-0.5%	-$4.35K	0.05%	316
2025 Q4	$1.01M	Hold	13,171	–	–	0.05%	304
2025 Q3	$684K	Buy	13,171 +5	+0%	+$244	0.04%	375
2025 Q2	$569K	Buy	13,166 +2	+0%	+$73	0.04%	334
2025 Q1	$455K	Sell	13,164 -36	-0.3%	-$1.21K	0.04%	333
2024 Q4	$362K	Buy	+13,200	New	+$341K	0.03%	358

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Syon Capital's BBIO Position: Q2 2026 in Review

Syon Capital reduced its BridgeBio Pharma (BBIO) stake by 2.6% in Q2 2026, selling an estimated $23.8K and leaving 12,771 shares worth $951K. The position accounts for 0.04% of the portfolio, ranked #372.

Syon Capital first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.01M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Syon Capital held 12,771 shares of BridgeBio Pharma worth $951K as of Q2 2026.
Syon Capital sold 340 BridgeBio Pharma shares in Q2 2026, an estimated $23.8K.
BridgeBio Pharma made up 0.04% of Syon Capital's portfolio in Q2 2026, its #372 holding.
Syon Capital first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
Syon Capital's BridgeBio Pharma position peaked at $1.01M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.